nodes	percent_of_prediction	percent_of_DWPC	metapath
Raltegravir—UGT1A1—Heme degradation—BLVRB—esophageal cancer	0.0556	0.119	CbGpPWpGaD
Raltegravir—UGT1A1—Porphyrin metabolism—BLVRB—esophageal cancer	0.0242	0.0518	CbGpPWpGaD
Raltegravir—UGT1A1—Codeine and Morphine Metabolism—ABCC2—esophageal cancer	0.0232	0.0498	CbGpPWpGaD
Raltegravir—CCR1—Chemokine receptors bind chemokines—CXCL2—esophageal cancer	0.0188	0.0402	CbGpPWpGaD
Raltegravir—UGT1A1—Heme degradation—HMOX1—esophageal cancer	0.0161	0.0346	CbGpPWpGaD
Raltegravir—UGT1A1—Irinotecan Pathway—ABCC2—esophageal cancer	0.0148	0.0318	CbGpPWpGaD
Raltegravir—UGT1A1—Codeine and Morphine Metabolism—ABCB1—esophageal cancer	0.0123	0.0264	CbGpPWpGaD
Raltegravir—UGT1A1—Aryl Hydrocarbon Receptor Pathway—ALDH3A1—esophageal cancer	0.0122	0.0262	CbGpPWpGaD
Raltegravir—UGT1A1—Estrogen metabolism—CYP1B1—esophageal cancer	0.00781	0.0168	CbGpPWpGaD
Raltegravir—UGT1A1—Constitutive Androstane Receptor Pathway—ABCC2—esophageal cancer	0.00765	0.0164	CbGpPWpGaD
Raltegravir—CCR1—GPCR ligand binding—ADCYAP1—esophageal cancer	0.0073	0.0157	CbGpPWpGaD
Raltegravir—CCR1—Peptide ligand-binding receptors—CXCL2—esophageal cancer	0.00706	0.0151	CbGpPWpGaD
Raltegravir—UGT1A1—Porphyrin metabolism—HMOX1—esophageal cancer	0.00702	0.0151	CbGpPWpGaD
Raltegravir—CCR1—G alpha (i) signalling events—GNG7—esophageal cancer	0.00676	0.0145	CbGpPWpGaD
Raltegravir—CCR1—Peptide ligand-binding receptors—ANXA1—esophageal cancer	0.00656	0.0141	CbGpPWpGaD
Raltegravir—CCR1—Peptide ligand-binding receptors—SST—esophageal cancer	0.00638	0.0137	CbGpPWpGaD
Raltegravir—CCR1—Peptide ligand-binding receptors—GHRL—esophageal cancer	0.00622	0.0133	CbGpPWpGaD
Raltegravir—UGT1A1—Constitutive Androstane Receptor Pathway—CYP2A6—esophageal cancer	0.00612	0.0131	CbGpPWpGaD
Raltegravir—CCR1—G alpha (i) signalling events—CXCL2—esophageal cancer	0.00595	0.0128	CbGpPWpGaD
Raltegravir—CCR1—G alpha (i) signalling events—ANXA1—esophageal cancer	0.00554	0.0119	CbGpPWpGaD
Raltegravir—CCR1—G alpha (i) signalling events—SST—esophageal cancer	0.00539	0.0116	CbGpPWpGaD
Raltegravir—UGT1A1—Aryl Hydrocarbon Receptor Pathway—NFE2L2—esophageal cancer	0.00532	0.0114	CbGpPWpGaD
Raltegravir—UGT1A1—NRF2 pathway—ALDH3A1—esophageal cancer	0.00485	0.0104	CbGpPWpGaD
Raltegravir—CCR1—Class A/1 (Rhodopsin-like receptors)—CXCL2—esophageal cancer	0.00473	0.0102	CbGpPWpGaD
Raltegravir—CCR1—Class A/1 (Rhodopsin-like receptors)—ANXA1—esophageal cancer	0.0044	0.00944	CbGpPWpGaD
Raltegravir—UGT1A1—NRF2 pathway—BLVRB—esophageal cancer	0.00433	0.00928	CbGpPWpGaD
Raltegravir—CCR1—Class A/1 (Rhodopsin-like receptors)—SST—esophageal cancer	0.00428	0.00919	CbGpPWpGaD
Raltegravir—CCR1—Class A/1 (Rhodopsin-like receptors)—GHRL—esophageal cancer	0.00417	0.00895	CbGpPWpGaD
Raltegravir—CCR1—GPCR downstream signaling—ADCYAP1—esophageal cancer	0.00413	0.00885	CbGpPWpGaD
Raltegravir—CCR1—GPCR ligand binding—GNG7—esophageal cancer	0.00409	0.00878	CbGpPWpGaD
Raltegravir—UGT1A1—Constitutive Androstane Receptor Pathway—ABCB1—esophageal cancer	0.00406	0.00871	CbGpPWpGaD
Raltegravir—CCR1—Signaling by GPCR—ADCYAP1—esophageal cancer	0.00375	0.00804	CbGpPWpGaD
Raltegravir—UGT1A1—Aryl Hydrocarbon Receptor Pathway—CYP1B1—esophageal cancer	0.00369	0.00791	CbGpPWpGaD
Raltegravir—UGT1A1—NRF2 pathway—PRDX1—esophageal cancer	0.00368	0.00789	CbGpPWpGaD
Raltegravir—CCR1—GPCR ligand binding—CXCL2—esophageal cancer	0.00361	0.00774	CbGpPWpGaD
Raltegravir—UGT1A1—Phase II conjugation—GSTO1—esophageal cancer	0.00355	0.00762	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—GDI2—esophageal cancer	0.00343	0.00737	CbGpPWpGaD
Raltegravir—CCR1—GPCR ligand binding—ANXA1—esophageal cancer	0.00335	0.00719	CbGpPWpGaD
Raltegravir—UGT1A1—NRF2 pathway—SLC39A6—esophageal cancer	0.00328	0.00703	CbGpPWpGaD
Raltegravir—CCR1—GPCR ligand binding—SST—esophageal cancer	0.00326	0.007	CbGpPWpGaD
Raltegravir—CCR1—GPCR ligand binding—GHRL—esophageal cancer	0.00318	0.00682	CbGpPWpGaD
Raltegravir—UGT1A1—NRF2 pathway—ADH7—esophageal cancer	0.00313	0.00671	CbGpPWpGaD
Raltegravir—UGT1A1—Aryl Hydrocarbon Receptor Pathway—BAX—esophageal cancer	0.00287	0.00617	CbGpPWpGaD
Raltegravir—UGT1A1—Phase II conjugation—GSTT1—esophageal cancer	0.00276	0.00591	CbGpPWpGaD
Raltegravir—UGT1A1—Biological oxidations—ADH7—esophageal cancer	0.00274	0.00589	CbGpPWpGaD
Raltegravir—CCR1—GPCR downstream signaling—AKAP13—esophageal cancer	0.00266	0.0057	CbGpPWpGaD
Raltegravir—Herpes zoster—Methotrexate—esophageal cancer	0.00259	0.00484	CcSEcCtD
Raltegravir—Depressed level of consciousness—Capecitabine—esophageal cancer	0.00253	0.00473	CcSEcCtD
Raltegravir—Face oedema—Cisplatin—esophageal cancer	0.00249	0.00466	CcSEcCtD
Raltegravir—CCR1—Signaling Pathways—KMT2D—esophageal cancer	0.00248	0.00533	CbGpPWpGaD
Raltegravir—Gingivitis—Methotrexate—esophageal cancer	0.00248	0.00465	CcSEcCtD
Raltegravir—CCR1—GPCR downstream signaling—PDE4D—esophageal cancer	0.00243	0.00522	CbGpPWpGaD
Raltegravir—CCR1—Signaling by GPCR—AKAP13—esophageal cancer	0.00241	0.00518	CbGpPWpGaD
Raltegravir—Blood creatinine increased—Cisplatin—esophageal cancer	0.00241	0.00452	CcSEcCtD
Raltegravir—UGT1A1—Biological oxidations—ADH1B—esophageal cancer	0.00241	0.00516	CbGpPWpGaD
Raltegravir—Neoplasm—Capecitabine—esophageal cancer	0.00237	0.00443	CcSEcCtD
Raltegravir—Breast disorder—Cisplatin—esophageal cancer	0.00233	0.00436	CcSEcCtD
Raltegravir—Aspartate aminotransferase increased—Cisplatin—esophageal cancer	0.00232	0.00435	CcSEcCtD
Raltegravir—CCR1—GPCR downstream signaling—GNG7—esophageal cancer	0.00231	0.00496	CbGpPWpGaD
Raltegravir—Nasopharyngitis—Cisplatin—esophageal cancer	0.0023	0.00432	CcSEcCtD
Raltegravir—UGT1A1—NRF2 pathway—ABCC2—esophageal cancer	0.00227	0.00488	CbGpPWpGaD
Raltegravir—Mental disability—Capecitabine—esophageal cancer	0.00227	0.00425	CcSEcCtD
Raltegravir—UGT1A1—Biological oxidations—CYP26A1—esophageal cancer	0.00224	0.0048	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—ADCYAP1—esophageal cancer	0.00221	0.00475	CbGpPWpGaD
Raltegravir—CCR1—Signaling by GPCR—PDE4D—esophageal cancer	0.00221	0.00474	CbGpPWpGaD
Raltegravir—UGT1A1—Metapathway biotransformation—CYP26A1—esophageal cancer	0.00221	0.00473	CbGpPWpGaD
Raltegravir—Sleep disorder—Capecitabine—esophageal cancer	0.00219	0.00411	CcSEcCtD
Raltegravir—Diabetes mellitus—Capecitabine—esophageal cancer	0.00218	0.00409	CcSEcCtD
Raltegravir—Blood alkaline phosphatase increased—Capecitabine—esophageal cancer	0.00218	0.00409	CcSEcCtD
Raltegravir—Gastroenteritis—Capecitabine—esophageal cancer	0.00214	0.00401	CcSEcCtD
Raltegravir—Abdominal discomfort—Cisplatin—esophageal cancer	0.00213	0.004	CcSEcCtD
Raltegravir—Herpes simplex—Methotrexate—esophageal cancer	0.00211	0.00396	CcSEcCtD
Raltegravir—Glossitis—Methotrexate—esophageal cancer	0.00211	0.00396	CcSEcCtD
Raltegravir—Hepatic failure—Capecitabine—esophageal cancer	0.00211	0.00396	CcSEcCtD
Raltegravir—UGT1A1—NRF2 pathway—NFE2L2—esophageal cancer	0.00211	0.00453	CbGpPWpGaD
Raltegravir—CCR1—Signaling by GPCR—GNG7—esophageal cancer	0.0021	0.00451	CbGpPWpGaD
Raltegravir—UGT1A1—Biological oxidations—GSTO1—esophageal cancer	0.00208	0.00446	CbGpPWpGaD
Raltegravir—UGT1A1—Metapathway biotransformation—GSTO1—esophageal cancer	0.00205	0.0044	CbGpPWpGaD
Raltegravir—CCR1—GPCR downstream signaling—CXCL2—esophageal cancer	0.00204	0.00437	CbGpPWpGaD
Raltegravir—Hot flush—Capecitabine—esophageal cancer	0.00203	0.0038	CcSEcCtD
Raltegravir—CCR1—Signaling Pathways—WWOX—esophageal cancer	0.00202	0.00434	CbGpPWpGaD
Raltegravir—Increased appetite—Capecitabine—esophageal cancer	0.00202	0.00379	CcSEcCtD
Raltegravir—Amnesia—Capecitabine—esophageal cancer	0.00202	0.00379	CcSEcCtD
Raltegravir—Menopausal symptoms—Capecitabine—esophageal cancer	0.00201	0.00377	CcSEcCtD
Raltegravir—Inflammation—Methotrexate—esophageal cancer	0.00201	0.00376	CcSEcCtD
Raltegravir—Renal impairment—Capecitabine—esophageal cancer	0.002	0.00374	CcSEcCtD
Raltegravir—Acute coronary syndrome—Cisplatin—esophageal cancer	0.00196	0.00367	CcSEcCtD
Raltegravir—Arthritis—Capecitabine—esophageal cancer	0.00195	0.00366	CcSEcCtD
Raltegravir—Renal failure—Cisplatin—esophageal cancer	0.00195	0.00366	CcSEcCtD
Raltegravir—Myocardial infarction—Cisplatin—esophageal cancer	0.00195	0.00365	CcSEcCtD
Raltegravir—Neuropathy peripheral—Cisplatin—esophageal cancer	0.00195	0.00365	CcSEcCtD
Raltegravir—Lethargy—Capecitabine—esophageal cancer	0.00194	0.00363	CcSEcCtD
Raltegravir—CCR1—Signaling Pathways—FKBP1A—esophageal cancer	0.00193	0.00413	CbGpPWpGaD
Raltegravir—Pain in extremity—Capecitabine—esophageal cancer	0.0019	0.00356	CcSEcCtD
Raltegravir—CCR1—GPCR downstream signaling—ANXA1—esophageal cancer	0.00189	0.00406	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—WIF1—esophageal cancer	0.00188	0.00404	CbGpPWpGaD
Raltegravir—Depressed level of consciousness—Methotrexate—esophageal cancer	0.00188	0.00352	CcSEcCtD
Raltegravir—Hepatobiliary disease—Cisplatin—esophageal cancer	0.00188	0.00352	CcSEcCtD
Raltegravir—Migraine—Capecitabine—esophageal cancer	0.00187	0.0035	CcSEcCtD
Raltegravir—CCR1—Signaling by GPCR—CXCL2—esophageal cancer	0.00185	0.00397	CbGpPWpGaD
Raltegravir—CCR1—GPCR downstream signaling—SST—esophageal cancer	0.00184	0.00395	CbGpPWpGaD
Raltegravir—Face oedema—Capecitabine—esophageal cancer	0.00183	0.00343	CcSEcCtD
Raltegravir—UGT1A1—NRF2 pathway—CYP2A6—esophageal cancer	0.00182	0.0039	CbGpPWpGaD
Raltegravir—Mood swings—Capecitabine—esophageal cancer	0.0018	0.00337	CcSEcCtD
Raltegravir—CCR1—GPCR downstream signaling—GHRL—esophageal cancer	0.0018	0.00385	CbGpPWpGaD
Raltegravir—Blood creatinine increased—Capecitabine—esophageal cancer	0.00178	0.00333	CcSEcCtD
Raltegravir—Neoplasm—Methotrexate—esophageal cancer	0.00176	0.0033	CcSEcCtD
Raltegravir—Urinary tract disorder—Cisplatin—esophageal cancer	0.00176	0.0033	CcSEcCtD
Raltegravir—Connective tissue disorder—Cisplatin—esophageal cancer	0.00175	0.00328	CcSEcCtD
Raltegravir—Urethral disorder—Cisplatin—esophageal cancer	0.00175	0.00327	CcSEcCtD
Raltegravir—Gynaecomastia—Methotrexate—esophageal cancer	0.00174	0.00326	CcSEcCtD
Raltegravir—Dry skin—Capecitabine—esophageal cancer	0.00174	0.00326	CcSEcCtD
Raltegravir—CCR1—Signaling Pathways—CSNK1A1—esophageal cancer	0.00174	0.00373	CbGpPWpGaD
Raltegravir—Abdominal pain upper—Capecitabine—esophageal cancer	0.00173	0.00325	CcSEcCtD
Raltegravir—CCR1—Signaling by GPCR—ANXA1—esophageal cancer	0.00172	0.00369	CbGpPWpGaD
Raltegravir—Visual impairment—Cisplatin—esophageal cancer	0.00172	0.00322	CcSEcCtD
Raltegravir—Breast disorder—Capecitabine—esophageal cancer	0.00172	0.00321	CcSEcCtD
Raltegravir—Aspartate aminotransferase increased—Capecitabine—esophageal cancer	0.00171	0.0032	CcSEcCtD
Raltegravir—Nasopharyngitis—Capecitabine—esophageal cancer	0.0017	0.00318	CcSEcCtD
Raltegravir—UGT1A1—Biological oxidations—ALDH2—esophageal cancer	0.00169	0.00364	CbGpPWpGaD
Raltegravir—Gastritis—Capecitabine—esophageal cancer	0.00168	0.00315	CcSEcCtD
Raltegravir—Alanine aminotransferase increased—Capecitabine—esophageal cancer	0.00167	0.00314	CcSEcCtD
Raltegravir—CCR1—Signaling by GPCR—SST—esophageal cancer	0.00167	0.00359	CbGpPWpGaD
Raltegravir—Eye disorder—Cisplatin—esophageal cancer	0.00167	0.00312	CcSEcCtD
Raltegravir—Tinnitus—Cisplatin—esophageal cancer	0.00166	0.00311	CcSEcCtD
Raltegravir—Lymphadenopathy—Methotrexate—esophageal cancer	0.00166	0.0031	CcSEcCtD
Raltegravir—Cardiac disorder—Cisplatin—esophageal cancer	0.00165	0.0031	CcSEcCtD
Raltegravir—Abdominal distension—Capecitabine—esophageal cancer	0.00165	0.00309	CcSEcCtD
Raltegravir—Influenza—Capecitabine—esophageal cancer	0.00164	0.00307	CcSEcCtD
Raltegravir—CCR1—Signaling by GPCR—GHRL—esophageal cancer	0.00163	0.0035	CbGpPWpGaD
Raltegravir—Diabetes mellitus—Methotrexate—esophageal cancer	0.00163	0.00304	CcSEcCtD
Raltegravir—CCR1—Signaling Pathways—PFN1—esophageal cancer	0.00162	0.00348	CbGpPWpGaD
Raltegravir—UGT1A1—Biological oxidations—GSTT1—esophageal cancer	0.00161	0.00346	CbGpPWpGaD
Raltegravir—Immune system disorder—Cisplatin—esophageal cancer	0.00161	0.00302	CcSEcCtD
Raltegravir—Mediastinal disorder—Cisplatin—esophageal cancer	0.00161	0.00301	CcSEcCtD
Raltegravir—UGT1A1—Biological oxidations—CYP2A6—esophageal cancer	0.00159	0.00342	CbGpPWpGaD
Raltegravir—Bronchitis—Capecitabine—esophageal cancer	0.00158	0.00296	CcSEcCtD
Raltegravir—Alopecia—Cisplatin—esophageal cancer	0.00157	0.00295	CcSEcCtD
Raltegravir—Abdominal discomfort—Capecitabine—esophageal cancer	0.00157	0.00295	CcSEcCtD
Raltegravir—Hepatic failure—Methotrexate—esophageal cancer	0.00157	0.00295	CcSEcCtD
Raltegravir—Malnutrition—Cisplatin—esophageal cancer	0.00155	0.00291	CcSEcCtD
Raltegravir—Erythema—Cisplatin—esophageal cancer	0.00155	0.00291	CcSEcCtD
Raltegravir—Neutropenia—Capecitabine—esophageal cancer	0.00153	0.00287	CcSEcCtD
Raltegravir—Flatulence—Cisplatin—esophageal cancer	0.00153	0.00286	CcSEcCtD
Raltegravir—Upper respiratory tract infection—Capecitabine—esophageal cancer	0.00153	0.00286	CcSEcCtD
Raltegravir—UGT1A1—Biological oxidations—PTGS1—esophageal cancer	0.00151	0.00324	CbGpPWpGaD
Raltegravir—Weight increased—Capecitabine—esophageal cancer	0.00149	0.0028	CcSEcCtD
Raltegravir—Weight decreased—Capecitabine—esophageal cancer	0.00148	0.00278	CcSEcCtD
Raltegravir—Hyperglycaemia—Capecitabine—esophageal cancer	0.00148	0.00277	CcSEcCtD
Raltegravir—Infestation—Capecitabine—esophageal cancer	0.00146	0.00274	CcSEcCtD
Raltegravir—Infestation NOS—Capecitabine—esophageal cancer	0.00146	0.00274	CcSEcCtD
Raltegravir—Depression—Capecitabine—esophageal cancer	0.00146	0.00273	CcSEcCtD
Raltegravir—CCR1—Signaling Pathways—ELMO1—esophageal cancer	0.00146	0.00313	CbGpPWpGaD
Raltegravir—Tremor—Cisplatin—esophageal cancer	0.00145	0.00272	CcSEcCtD
Raltegravir—Stevens-Johnson syndrome—Capecitabine—esophageal cancer	0.00145	0.00272	CcSEcCtD
Raltegravir—Acute coronary syndrome—Capecitabine—esophageal cancer	0.00144	0.0027	CcSEcCtD
Raltegravir—Lethargy—Methotrexate—esophageal cancer	0.00144	0.0027	CcSEcCtD
Raltegravir—Ill-defined disorder—Cisplatin—esophageal cancer	0.00144	0.0027	CcSEcCtD
Raltegravir—Renal failure—Capecitabine—esophageal cancer	0.00144	0.00269	CcSEcCtD
Raltegravir—Myocardial infarction—Capecitabine—esophageal cancer	0.00143	0.00269	CcSEcCtD
Raltegravir—Neuropathy peripheral—Capecitabine—esophageal cancer	0.00143	0.00269	CcSEcCtD
Raltegravir—Anaemia—Cisplatin—esophageal cancer	0.00143	0.00269	CcSEcCtD
Raltegravir—CCR1—Signaling Pathways—AKAP13—esophageal cancer	0.00143	0.00306	CbGpPWpGaD
Raltegravir—Malaise—Cisplatin—esophageal cancer	0.0014	0.00262	CcSEcCtD
Raltegravir—Haematuria—Capecitabine—esophageal cancer	0.0014	0.00261	CcSEcCtD
Raltegravir—Hepatobiliary disease—Capecitabine—esophageal cancer	0.00138	0.00259	CcSEcCtD
Raltegravir—UGT1A1—Aryl Hydrocarbon Receptor Pathway—EP300—esophageal cancer	0.00138	0.00297	CbGpPWpGaD
Raltegravir—Epistaxis—Capecitabine—esophageal cancer	0.00138	0.00259	CcSEcCtD
Raltegravir—Mood swings—Methotrexate—esophageal cancer	0.00134	0.00251	CcSEcCtD
Raltegravir—Myalgia—Cisplatin—esophageal cancer	0.00132	0.00247	CcSEcCtD
Raltegravir—Anxiety—Cisplatin—esophageal cancer	0.00132	0.00247	CcSEcCtD
Raltegravir—CCR1—Signaling Pathways—HIST1H2BM—esophageal cancer	0.00132	0.00282	CbGpPWpGaD
Raltegravir—Hepatitis—Capecitabine—esophageal cancer	0.00131	0.00246	CcSEcCtD
Raltegravir—Unspecified disorder of skin and subcutaneous tissue—Cisplatin—esophageal cancer	0.00131	0.00246	CcSEcCtD
Raltegravir—Hypoaesthesia—Capecitabine—esophageal cancer	0.00131	0.00245	CcSEcCtD
Raltegravir—Discomfort—Cisplatin—esophageal cancer	0.00131	0.00244	CcSEcCtD
Raltegravir—CCR1—Signaling Pathways—PDE4D—esophageal cancer	0.0013	0.0028	CbGpPWpGaD
Raltegravir—Urinary tract disorder—Capecitabine—esophageal cancer	0.0013	0.00243	CcSEcCtD
Raltegravir—Oedema peripheral—Capecitabine—esophageal cancer	0.00129	0.00242	CcSEcCtD
Raltegravir—Connective tissue disorder—Capecitabine—esophageal cancer	0.00129	0.00242	CcSEcCtD
Raltegravir—Urethral disorder—Capecitabine—esophageal cancer	0.00129	0.00241	CcSEcCtD
Raltegravir—UGT1A1—Biological oxidations—CYP1B1—esophageal cancer	0.00128	0.00276	CbGpPWpGaD
Raltegravir—Breast disorder—Methotrexate—esophageal cancer	0.00128	0.00239	CcSEcCtD
Raltegravir—UGT1A1—NRF2 pathway—TGFBR2—esophageal cancer	0.00127	0.00273	CbGpPWpGaD
Raltegravir—UGT1A1—Metapathway biotransformation—CYP1B1—esophageal cancer	0.00127	0.00272	CbGpPWpGaD
Raltegravir—Visual impairment—Capecitabine—esophageal cancer	0.00127	0.00237	CcSEcCtD
Raltegravir—Infection—Cisplatin—esophageal cancer	0.00126	0.00236	CcSEcCtD
Raltegravir—UGT1A1—NRF2 pathway—HMOX1—esophageal cancer	0.00126	0.0027	CbGpPWpGaD
Raltegravir—Erythema multiforme—Capecitabine—esophageal cancer	0.00124	0.00233	CcSEcCtD
Raltegravir—Nervous system disorder—Cisplatin—esophageal cancer	0.00124	0.00233	CcSEcCtD
Raltegravir—CCR1—Signaling Pathways—GNG7—esophageal cancer	0.00124	0.00266	CbGpPWpGaD
Raltegravir—Thrombocytopenia—Cisplatin—esophageal cancer	0.00124	0.00232	CcSEcCtD
Raltegravir—Skin disorder—Cisplatin—esophageal cancer	0.00123	0.0023	CcSEcCtD
Raltegravir—Eye disorder—Capecitabine—esophageal cancer	0.00123	0.0023	CcSEcCtD
Raltegravir—Tinnitus—Capecitabine—esophageal cancer	0.00122	0.00229	CcSEcCtD
Raltegravir—Hyperhidrosis—Cisplatin—esophageal cancer	0.00122	0.00229	CcSEcCtD
Raltegravir—Cardiac disorder—Capecitabine—esophageal cancer	0.00122	0.00228	CcSEcCtD
Raltegravir—Eosinophilia—Methotrexate—esophageal cancer	0.00121	0.00227	CcSEcCtD
Raltegravir—UGT1A1—Biological oxidations—CYP19A1—esophageal cancer	0.00121	0.00259	CbGpPWpGaD
Raltegravir—Angiopathy—Capecitabine—esophageal cancer	0.00119	0.00223	CcSEcCtD
Raltegravir—UGT1A1—Metapathway biotransformation—CYP19A1—esophageal cancer	0.00119	0.00256	CbGpPWpGaD
Raltegravir—Immune system disorder—Capecitabine—esophageal cancer	0.00119	0.00222	CcSEcCtD
Raltegravir—Mediastinal disorder—Capecitabine—esophageal cancer	0.00118	0.00222	CcSEcCtD
Raltegravir—Chills—Capecitabine—esophageal cancer	0.00118	0.00221	CcSEcCtD
Raltegravir—UGT1A1—Aryl Hydrocarbon Receptor Pathway—EGFR—esophageal cancer	0.00118	0.00253	CbGpPWpGaD
Raltegravir—Abdominal discomfort—Methotrexate—esophageal cancer	0.00117	0.00219	CcSEcCtD
Raltegravir—CCR1—Signaling Pathways—XIAP—esophageal cancer	0.00116	0.00249	CbGpPWpGaD
Raltegravir—Alopecia—Capecitabine—esophageal cancer	0.00116	0.00217	CcSEcCtD
Raltegravir—Musculoskeletal discomfort—Cisplatin—esophageal cancer	0.00115	0.00216	CcSEcCtD
Raltegravir—Mental disorder—Capecitabine—esophageal cancer	0.00115	0.00216	CcSEcCtD
Raltegravir—Erythema—Capecitabine—esophageal cancer	0.00114	0.00214	CcSEcCtD
Raltegravir—Malnutrition—Capecitabine—esophageal cancer	0.00114	0.00214	CcSEcCtD
Raltegravir—Neutropenia—Methotrexate—esophageal cancer	0.00114	0.00214	CcSEcCtD
Raltegravir—Paraesthesia—Cisplatin—esophageal cancer	0.00114	0.00213	CcSEcCtD
Raltegravir—Upper respiratory tract infection—Methotrexate—esophageal cancer	0.00114	0.00213	CcSEcCtD
Raltegravir—Flatulence—Capecitabine—esophageal cancer	0.00113	0.00211	CcSEcCtD
Raltegravir—Erectile dysfunction—Methotrexate—esophageal cancer	0.00113	0.00211	CcSEcCtD
Raltegravir—Dysgeusia—Capecitabine—esophageal cancer	0.00112	0.0021	CcSEcCtD
Raltegravir—Back pain—Capecitabine—esophageal cancer	0.00111	0.00207	CcSEcCtD
Raltegravir—Decreased appetite—Cisplatin—esophageal cancer	0.0011	0.00206	CcSEcCtD
Raltegravir—CCR1—Signaling Pathways—CTNNA1—esophageal cancer	0.0011	0.00236	CbGpPWpGaD
Raltegravir—Gastrointestinal disorder—Cisplatin—esophageal cancer	0.00109	0.00205	CcSEcCtD
Raltegravir—CCR1—Signaling Pathways—CXCL2—esophageal cancer	0.00109	0.00234	CbGpPWpGaD
Raltegravir—Infestation NOS—Methotrexate—esophageal cancer	0.00109	0.00204	CcSEcCtD
Raltegravir—Infestation—Methotrexate—esophageal cancer	0.00109	0.00204	CcSEcCtD
Raltegravir—Depression—Methotrexate—esophageal cancer	0.00109	0.00203	CcSEcCtD
Raltegravir—Pain—Cisplatin—esophageal cancer	0.00108	0.00203	CcSEcCtD
Raltegravir—Stevens-Johnson syndrome—Methotrexate—esophageal cancer	0.00108	0.00202	CcSEcCtD
Raltegravir—Tremor—Capecitabine—esophageal cancer	0.00107	0.00201	CcSEcCtD
Raltegravir—Renal failure—Methotrexate—esophageal cancer	0.00107	0.00201	CcSEcCtD
Raltegravir—Ill-defined disorder—Capecitabine—esophageal cancer	0.00106	0.00199	CcSEcCtD
Raltegravir—Anaemia—Capecitabine—esophageal cancer	0.00106	0.00198	CcSEcCtD
Raltegravir—Feeling abnormal—Cisplatin—esophageal cancer	0.00104	0.00195	CcSEcCtD
Raltegravir—Haematuria—Methotrexate—esophageal cancer	0.00104	0.00195	CcSEcCtD
Raltegravir—Malaise—Capecitabine—esophageal cancer	0.00103	0.00193	CcSEcCtD
Raltegravir—Hepatobiliary disease—Methotrexate—esophageal cancer	0.00103	0.00193	CcSEcCtD
Raltegravir—Epistaxis—Methotrexate—esophageal cancer	0.00103	0.00192	CcSEcCtD
Raltegravir—Vertigo—Capecitabine—esophageal cancer	0.00103	0.00192	CcSEcCtD
Raltegravir—CCR1—Signaling Pathways—PSME1—esophageal cancer	0.00102	0.00219	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—PSME2—esophageal cancer	0.00102	0.00219	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—ANXA1—esophageal cancer	0.00102	0.00218	CbGpPWpGaD
Raltegravir—Palpitations—Capecitabine—esophageal cancer	0.00101	0.00189	CcSEcCtD
Raltegravir—Body temperature increased—Cisplatin—esophageal cancer	0.001	0.00187	CcSEcCtD
Raltegravir—Cough—Capecitabine—esophageal cancer	0.000998	0.00187	CcSEcCtD
Raltegravir—CCR1—Signaling Pathways—SST—esophageal cancer	0.000988	0.00212	CbGpPWpGaD
Raltegravir—Hypertension—Capecitabine—esophageal cancer	0.000987	0.00185	CcSEcCtD
Raltegravir—Hepatitis—Methotrexate—esophageal cancer	0.000978	0.00183	CcSEcCtD
Raltegravir—Arthralgia—Capecitabine—esophageal cancer	0.000974	0.00182	CcSEcCtD
Raltegravir—Chest pain—Capecitabine—esophageal cancer	0.000974	0.00182	CcSEcCtD
Raltegravir—Myalgia—Capecitabine—esophageal cancer	0.000974	0.00182	CcSEcCtD
Raltegravir—Anxiety—Capecitabine—esophageal cancer	0.00097	0.00182	CcSEcCtD
Raltegravir—Unspecified disorder of skin and subcutaneous tissue—Capecitabine—esophageal cancer	0.000967	0.00181	CcSEcCtD
Raltegravir—Urinary tract disorder—Methotrexate—esophageal cancer	0.000966	0.00181	CcSEcCtD
Raltegravir—CCR1—Signaling Pathways—NOTCH3—esophageal cancer	0.000963	0.00207	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—GHRL—esophageal cancer	0.000963	0.00207	CbGpPWpGaD
Raltegravir—Discomfort—Capecitabine—esophageal cancer	0.000962	0.0018	CcSEcCtD
Raltegravir—Urethral disorder—Methotrexate—esophageal cancer	0.000959	0.0018	CcSEcCtD
Raltegravir—Dry mouth—Capecitabine—esophageal cancer	0.000952	0.00178	CcSEcCtD
Raltegravir—CCR1—Signaling Pathways—FBXW7—esophageal cancer	0.000948	0.00203	CbGpPWpGaD
Raltegravir—Visual impairment—Methotrexate—esophageal cancer	0.000943	0.00177	CcSEcCtD
Raltegravir—Confusional state—Capecitabine—esophageal cancer	0.000941	0.00176	CcSEcCtD
Raltegravir—Hypersensitivity—Cisplatin—esophageal cancer	0.000933	0.00175	CcSEcCtD
Raltegravir—Infection—Capecitabine—esophageal cancer	0.000927	0.00174	CcSEcCtD
Raltegravir—Erythema multiforme—Methotrexate—esophageal cancer	0.000925	0.00173	CcSEcCtD
Raltegravir—Nervous system disorder—Capecitabine—esophageal cancer	0.000915	0.00171	CcSEcCtD
Raltegravir—Eye disorder—Methotrexate—esophageal cancer	0.000914	0.00171	CcSEcCtD
Raltegravir—Thrombocytopenia—Capecitabine—esophageal cancer	0.000914	0.00171	CcSEcCtD
Raltegravir—Tinnitus—Methotrexate—esophageal cancer	0.000912	0.00171	CcSEcCtD
Raltegravir—Asthenia—Cisplatin—esophageal cancer	0.000908	0.0017	CcSEcCtD
Raltegravir—Cardiac disorder—Methotrexate—esophageal cancer	0.000908	0.0017	CcSEcCtD
Raltegravir—Skin disorder—Capecitabine—esophageal cancer	0.000907	0.0017	CcSEcCtD
Raltegravir—Hyperhidrosis—Capecitabine—esophageal cancer	0.000902	0.00169	CcSEcCtD
Raltegravir—Angiopathy—Methotrexate—esophageal cancer	0.000887	0.00166	CcSEcCtD
Raltegravir—Immune system disorder—Methotrexate—esophageal cancer	0.000883	0.00165	CcSEcCtD
Raltegravir—Mediastinal disorder—Methotrexate—esophageal cancer	0.000881	0.00165	CcSEcCtD
Raltegravir—Chills—Methotrexate—esophageal cancer	0.000878	0.00164	CcSEcCtD
Raltegravir—Diarrhoea—Cisplatin—esophageal cancer	0.000866	0.00162	CcSEcCtD
Raltegravir—Alopecia—Methotrexate—esophageal cancer	0.000864	0.00162	CcSEcCtD
Raltegravir—CCR1—Signaling Pathways—NOTCH2—esophageal cancer	0.000864	0.00185	CbGpPWpGaD
Raltegravir—Mental disorder—Methotrexate—esophageal cancer	0.000857	0.0016	CcSEcCtD
Raltegravir—Malnutrition—Methotrexate—esophageal cancer	0.000851	0.00159	CcSEcCtD
Raltegravir—Erythema—Methotrexate—esophageal cancer	0.000851	0.00159	CcSEcCtD
Raltegravir—Musculoskeletal discomfort—Capecitabine—esophageal cancer	0.00085	0.00159	CcSEcCtD
Raltegravir—Insomnia—Capecitabine—esophageal cancer	0.000844	0.00158	CcSEcCtD
Raltegravir—Paraesthesia—Capecitabine—esophageal cancer	0.000838	0.00157	CcSEcCtD
Raltegravir—Dysgeusia—Methotrexate—esophageal cancer	0.000834	0.00156	CcSEcCtD
Raltegravir—Back pain—Methotrexate—esophageal cancer	0.000824	0.00154	CcSEcCtD
Raltegravir—Dyspepsia—Capecitabine—esophageal cancer	0.000822	0.00154	CcSEcCtD
Raltegravir—Decreased appetite—Capecitabine—esophageal cancer	0.000811	0.00152	CcSEcCtD
Raltegravir—Gastrointestinal disorder—Capecitabine—esophageal cancer	0.000806	0.00151	CcSEcCtD
Raltegravir—Vomiting—Cisplatin—esophageal cancer	0.000805	0.00151	CcSEcCtD
Raltegravir—Fatigue—Capecitabine—esophageal cancer	0.000805	0.00151	CcSEcCtD
Raltegravir—Rash—Cisplatin—esophageal cancer	0.000798	0.0015	CcSEcCtD
Raltegravir—Constipation—Capecitabine—esophageal cancer	0.000798	0.0015	CcSEcCtD
Raltegravir—Pain—Capecitabine—esophageal cancer	0.000798	0.0015	CcSEcCtD
Raltegravir—Dermatitis—Cisplatin—esophageal cancer	0.000798	0.00149	CcSEcCtD
Raltegravir—Ill-defined disorder—Methotrexate—esophageal cancer	0.00079	0.00148	CcSEcCtD
Raltegravir—Anaemia—Methotrexate—esophageal cancer	0.000787	0.00147	CcSEcCtD
Raltegravir—Feeling abnormal—Capecitabine—esophageal cancer	0.000769	0.00144	CcSEcCtD
Raltegravir—Malaise—Methotrexate—esophageal cancer	0.000768	0.00144	CcSEcCtD
Raltegravir—CCR1—Signaling Pathways—TGFBR2—esophageal cancer	0.000766	0.00164	CbGpPWpGaD
Raltegravir—Vertigo—Methotrexate—esophageal cancer	0.000765	0.00143	CcSEcCtD
Raltegravir—Gastrointestinal pain—Capecitabine—esophageal cancer	0.000763	0.00143	CcSEcCtD
Raltegravir—Nausea—Cisplatin—esophageal cancer	0.000752	0.00141	CcSEcCtD
Raltegravir—Cough—Methotrexate—esophageal cancer	0.000743	0.00139	CcSEcCtD
Raltegravir—Urticaria—Capecitabine—esophageal cancer	0.000742	0.00139	CcSEcCtD
Raltegravir—Abdominal pain—Capecitabine—esophageal cancer	0.000738	0.00138	CcSEcCtD
Raltegravir—Body temperature increased—Capecitabine—esophageal cancer	0.000738	0.00138	CcSEcCtD
Raltegravir—CCR1—Signaling Pathways—SMAD4—esophageal cancer	0.000726	0.00156	CbGpPWpGaD
Raltegravir—Arthralgia—Methotrexate—esophageal cancer	0.000725	0.00136	CcSEcCtD
Raltegravir—Myalgia—Methotrexate—esophageal cancer	0.000725	0.00136	CcSEcCtD
Raltegravir—Chest pain—Methotrexate—esophageal cancer	0.000725	0.00136	CcSEcCtD
Raltegravir—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—esophageal cancer	0.00072	0.00135	CcSEcCtD
Raltegravir—Discomfort—Methotrexate—esophageal cancer	0.000716	0.00134	CcSEcCtD
Raltegravir—Confusional state—Methotrexate—esophageal cancer	0.000701	0.00131	CcSEcCtD
Raltegravir—Infection—Methotrexate—esophageal cancer	0.00069	0.00129	CcSEcCtD
Raltegravir—Hypersensitivity—Capecitabine—esophageal cancer	0.000688	0.00129	CcSEcCtD
Raltegravir—Nervous system disorder—Methotrexate—esophageal cancer	0.000681	0.00128	CcSEcCtD
Raltegravir—Thrombocytopenia—Methotrexate—esophageal cancer	0.00068	0.00127	CcSEcCtD
Raltegravir—Skin disorder—Methotrexate—esophageal cancer	0.000675	0.00126	CcSEcCtD
Raltegravir—Hyperhidrosis—Methotrexate—esophageal cancer	0.000672	0.00126	CcSEcCtD
Raltegravir—Asthenia—Capecitabine—esophageal cancer	0.00067	0.00125	CcSEcCtD
Raltegravir—Pruritus—Capecitabine—esophageal cancer	0.00066	0.00124	CcSEcCtD
Raltegravir—UGT1A1—Metabolism—SLC52A3—esophageal cancer	0.000649	0.00139	CbGpPWpGaD
Raltegravir—UGT1A1—Metabolism—BLVRB—esophageal cancer	0.000649	0.00139	CbGpPWpGaD
Raltegravir—Diarrhoea—Capecitabine—esophageal cancer	0.000639	0.0012	CcSEcCtD
Raltegravir—Musculoskeletal discomfort—Methotrexate—esophageal cancer	0.000633	0.00119	CcSEcCtD
Raltegravir—Insomnia—Methotrexate—esophageal cancer	0.000628	0.00118	CcSEcCtD
Raltegravir—Paraesthesia—Methotrexate—esophageal cancer	0.000624	0.00117	CcSEcCtD
Raltegravir—Somnolence—Methotrexate—esophageal cancer	0.000618	0.00116	CcSEcCtD
Raltegravir—Dizziness—Capecitabine—esophageal cancer	0.000617	0.00116	CcSEcCtD
Raltegravir—Dyspepsia—Methotrexate—esophageal cancer	0.000612	0.00115	CcSEcCtD
Raltegravir—Decreased appetite—Methotrexate—esophageal cancer	0.000604	0.00113	CcSEcCtD
Raltegravir—Gastrointestinal disorder—Methotrexate—esophageal cancer	0.0006	0.00112	CcSEcCtD
Raltegravir—Fatigue—Methotrexate—esophageal cancer	0.000599	0.00112	CcSEcCtD
Raltegravir—Pain—Methotrexate—esophageal cancer	0.000594	0.00111	CcSEcCtD
Raltegravir—CCR1—Signaling Pathways—HIF1A—esophageal cancer	0.000594	0.00127	CbGpPWpGaD
Raltegravir—Vomiting—Capecitabine—esophageal cancer	0.000593	0.00111	CcSEcCtD
Raltegravir—Rash—Capecitabine—esophageal cancer	0.000589	0.0011	CcSEcCtD
Raltegravir—Dermatitis—Capecitabine—esophageal cancer	0.000588	0.0011	CcSEcCtD
Raltegravir—Headache—Capecitabine—esophageal cancer	0.000585	0.0011	CcSEcCtD
Raltegravir—Feeling abnormal—Methotrexate—esophageal cancer	0.000573	0.00107	CcSEcCtD
Raltegravir—Gastrointestinal pain—Methotrexate—esophageal cancer	0.000568	0.00106	CcSEcCtD
Raltegravir—CCR1—Signaling Pathways—KDR—esophageal cancer	0.000568	0.00122	CbGpPWpGaD
Raltegravir—Nausea—Capecitabine—esophageal cancer	0.000554	0.00104	CcSEcCtD
Raltegravir—Urticaria—Methotrexate—esophageal cancer	0.000552	0.00103	CcSEcCtD
Raltegravir—UGT1A1—Metabolism—SLC10A2—esophageal cancer	0.000552	0.00118	CbGpPWpGaD
Raltegravir—UGT1A1—Metabolism—CA1—esophageal cancer	0.000552	0.00118	CbGpPWpGaD
Raltegravir—Body temperature increased—Methotrexate—esophageal cancer	0.000549	0.00103	CcSEcCtD
Raltegravir—Abdominal pain—Methotrexate—esophageal cancer	0.000549	0.00103	CcSEcCtD
Raltegravir—CCR1—Signaling Pathways—NOTCH1—esophageal cancer	0.000535	0.00115	CbGpPWpGaD
Raltegravir—Hypersensitivity—Methotrexate—esophageal cancer	0.000512	0.000959	CcSEcCtD
Raltegravir—UGT1A1—Metabolism—CA2—esophageal cancer	0.000505	0.00108	CbGpPWpGaD
Raltegravir—Asthenia—Methotrexate—esophageal cancer	0.000499	0.000934	CcSEcCtD
Raltegravir—Pruritus—Methotrexate—esophageal cancer	0.000492	0.000921	CcSEcCtD
Raltegravir—CCR1—Signaling Pathways—CREBBP—esophageal cancer	0.000485	0.00104	CbGpPWpGaD
Raltegravir—CCR1—Signaling by GPCR—EGFR—esophageal cancer	0.000476	0.00102	CbGpPWpGaD
Raltegravir—Diarrhoea—Methotrexate—esophageal cancer	0.000475	0.00089	CcSEcCtD
Raltegravir—UGT1A1—Metabolism—PLCE1—esophageal cancer	0.000469	0.00101	CbGpPWpGaD
Raltegravir—UGT1A1—Metabolism—ADH7—esophageal cancer	0.000469	0.00101	CbGpPWpGaD
Raltegravir—Dizziness—Methotrexate—esophageal cancer	0.000459	0.000861	CcSEcCtD
Raltegravir—CCR1—GPCR downstream signaling—PIK3CA—esophageal cancer	0.000455	0.000977	CbGpPWpGaD
Raltegravir—Vomiting—Methotrexate—esophageal cancer	0.000442	0.000827	CcSEcCtD
Raltegravir—Rash—Methotrexate—esophageal cancer	0.000438	0.000821	CcSEcCtD
Raltegravir—Dermatitis—Methotrexate—esophageal cancer	0.000438	0.00082	CcSEcCtD
Raltegravir—Headache—Methotrexate—esophageal cancer	0.000435	0.000815	CcSEcCtD
Raltegravir—CCR1—Signaling Pathways—NOS3—esophageal cancer	0.000434	0.000931	CbGpPWpGaD
Raltegravir—CCR1—Signaling by GPCR—PIK3CA—esophageal cancer	0.000414	0.000887	CbGpPWpGaD
Raltegravir—Nausea—Methotrexate—esophageal cancer	0.000413	0.000773	CcSEcCtD
Raltegravir—UGT1A1—Metabolism—ADH1B—esophageal cancer	0.000411	0.000883	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—ERBB2—esophageal cancer	0.000406	0.000871	CbGpPWpGaD
Raltegravir—UGT1A1—Metabolism—TYMP—esophageal cancer	0.000393	0.000843	CbGpPWpGaD
Raltegravir—UGT1A1—Metabolism—CYP26A1—esophageal cancer	0.000382	0.00082	CbGpPWpGaD
Raltegravir—UGT1A1—Metabolism—ALOX15—esophageal cancer	0.000373	0.0008	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—CCND1—esophageal cancer	0.000359	0.00077	CbGpPWpGaD
Raltegravir—UGT1A1—Metabolism—GSTO1—esophageal cancer	0.000356	0.000763	CbGpPWpGaD
Raltegravir—UGT1A1—Metabolism—TPI1—esophageal cancer	0.000356	0.000763	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—CDKN1A—esophageal cancer	0.000347	0.000745	CbGpPWpGaD
Raltegravir—UGT1A1—Metabolism—ALDOB—esophageal cancer	0.000341	0.000731	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—EP300—esophageal cancer	0.00033	0.000709	CbGpPWpGaD
Raltegravir—UGT1A1—Metabolism—GAPDH—esophageal cancer	0.000328	0.000704	CbGpPWpGaD
Raltegravir—UGT1A1—Metabolism—CRABP1—esophageal cancer	0.000325	0.000698	CbGpPWpGaD
Raltegravir—UGT1A1—Metabolism—GNG7—esophageal cancer	0.000309	0.000664	CbGpPWpGaD
Raltegravir—UGT1A1—Metabolism—ALDH2—esophageal cancer	0.00029	0.000622	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—MYC—esophageal cancer	0.000288	0.000617	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—EGFR—esophageal cancer	0.000281	0.000604	CbGpPWpGaD
Raltegravir—UGT1A1—Metabolism—GSTT1—esophageal cancer	0.000276	0.000591	CbGpPWpGaD
Raltegravir—UGT1A1—Metabolism—CYP2A6—esophageal cancer	0.000272	0.000585	CbGpPWpGaD
Raltegravir—UGT1A1—Metabolism—ENO1—esophageal cancer	0.000258	0.000554	CbGpPWpGaD
Raltegravir—UGT1A1—Metabolism—PTGS1—esophageal cancer	0.000258	0.000554	CbGpPWpGaD
Raltegravir—UGT1A1—Metabolism—PSME2—esophageal cancer	0.000255	0.000546	CbGpPWpGaD
Raltegravir—UGT1A1—Metabolism—PSME1—esophageal cancer	0.000255	0.000546	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—PIK3CA—esophageal cancer	0.000244	0.000524	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—TP53—esophageal cancer	0.000236	0.000507	CbGpPWpGaD
Raltegravir—UGT1A1—Metabolism—CYP1B1—esophageal cancer	0.00022	0.000471	CbGpPWpGaD
Raltegravir—UGT1A1—Metabolism—CYP19A1—esophageal cancer	0.000207	0.000443	CbGpPWpGaD
Raltegravir—UGT1A1—Metabolism—HMOX1—esophageal cancer	0.000188	0.000404	CbGpPWpGaD
Raltegravir—UGT1A1—Metabolism—ABCB1—esophageal cancer	0.000181	0.000388	CbGpPWpGaD
Raltegravir—UGT1A1—Metabolism—CREBBP—esophageal cancer	0.000121	0.000259	CbGpPWpGaD
Raltegravir—UGT1A1—Metabolism—NOS3—esophageal cancer	0.000108	0.000232	CbGpPWpGaD
Raltegravir—UGT1A1—Metabolism—PTGS2—esophageal cancer	9.9e-05	0.000212	CbGpPWpGaD
Raltegravir—UGT1A1—Metabolism—EP300—esophageal cancer	8.23e-05	0.000177	CbGpPWpGaD
Raltegravir—UGT1A1—Metabolism—PIK3CA—esophageal cancer	6.09e-05	0.000131	CbGpPWpGaD
